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Abstract: Antazoline (ANT) was recently shown to be an effective and safe antiarrhythmic drug 
in the termination of atrial fibrillation. However, the drug is still not listed in clinical guidelines. 
No data on ANT metabolism in humans is available. We used liquid chromatography coupled with 
tandem mass spectrometry to identify and characterize metabolites of ANT. We analyzed plasma of 
volunteers following a single intravenous administration of 100 mg of ANT mesylate and in in vitro 
cultures of human hepatocytes. We revealed that ANT was transformed into at least 15 metabolites 
and we investigated the role of cytochrome P450 isoforms. CYP2D6 was the main one involved in the 
fast metabolism of ANT. The biotransformation of ANT by CYP2C19 was much slower. The main 
Phase I metabolite was M1 formed by the removal of phenyl and metabolite M2 with hydroxyl in 
the para position of phenyl. Glucuronidation was the leading Phase II metabolism. Further study 
on pharmacokinetics of the metabolites would allow us to better understand the activity profile of 
ANT and to predict its potential clinical applications. Ultimately, further investigation of the activity 
profile of the new hydroxylated M2 metabolite of ANT might result in an active substance with a 
different pharmacological profile than the parent molecule, and potentially a new drug candidate.
Keywords: antazoline; atrial fibrillation; metabolism; cytochrome P450 isoform; liquid chromatography 
coupled with tandem mass spectrometry
1. Introduction
Antazoline (ANT) is a first-generation antiarrhythmic and anticholinergic agent that is 
well-established in clinics. It was originally used for the management of acute allergic reactions [1] . 
However, recent data showed that ANT is also very effective in the termination of atrial fibrillation 
(AF) [2- 4]. Recently, retrospective analysis of the randomized controlled trial has been conducted 
and showed high effectiveness of ANT in the rapid conversion of recent-onset AF to sinus rhythm [2]. 
Additionally, ANT was effective in the termination of AF during accessory pathway ablation [5] as well 
as pulmonary veins isolation [6]. ANT was also shown as an effective and safe option in the termination
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of AF in patients with stable coronary artery disease [7]. ANT is usually well tolerated, however, 
some mild side effects occurred. The most common side effects of ANT include transient heat sensation 
in the throat and lower abdomen, vertigo, hypotension, or nausea, and vomiting [6,8]. There has 
been a case report on ANT causing granulocytopenia. However, in addition to ANT, the patient was 
given penicillamine, which might cause granulocytopenia, or it could be due to the additive effect of 
penicillamine and ANT [9].
Despite numerous data showing that ANT is an effective and safe antiarrhythmic drug, it is 
still not listed in the clinical guidelines [10]. Most of the information about ANT is based on clinical 
data. During the last decade, new data emerged and shed more light on the antiarrhythmic function 
of ANT. The first randomized study was conducted which confirmed the high efficacy and safety 
of ANT in the termination of AF [2]. Recently, data on the pharmacokinetics of single intravenous 
administration of 100 mg of ANT mesylate in healthy volunteers presented the fast elimination and 
the relatively high volume of distribution of the drug [11]. ANT also prolonged P wave, QRS duration, 
and QT/QTc, which corresponds with drug-induced prolongation of conduction (P wave and QRS) 
and repolarization (QT/QTc) [8]. During the ablation of supraventricular arrhythmias, ANT led to 
an increase in sinus rhythm and prolonged interatrial conduction [12]. A lack of impact of ANT on 
conduction between pulmonary vein potentials and atrial muscle was also shown [13]. Moreover, 
in an animal model of the drug-induced increased atrial refractory period, ANT reduced interatrial 
conduction time which was associated with high AF suppression rate [14]. However, many questions 
regarding the mechanism of action of ANT remain to be answered. For instance, it is not known 
whether ANT is the active agent itself, or the pharmacological effects are also related to some active 
metabolites. Scarce data on the metabolic profile of ANT and no data on their activities are available.
Metabolism is the process of biotransformation of a drug substance by various bodily systems. 
Two phases of the metabolism of pharmaceuticals are frequently recognized. Phase I is carried out mostly 
by microsomal monooxygenases, with the main role played by cytochrome P450 (CYP P450). This phase 
predominantly involves hydrolysis, reduction, and oxidation, and it introduces a polar substituent into 
the molecule. Phase II includes glucuronide, sulfate, glutathione, and amino acid conjugation as well as 
acetylation and methylation to form water-soluble products, usually less toxic and more easily excreted 
than the parent drug substance [15]. It is essential to evaluate the pharmacodynamic consequences of 
these metabolic reactions. Biotransformation mainly involves inactivation of the xenobiotics. It can also 
result in the formation of the active metabolite (e.g., in case of leflunomide). Moreover, due to higher 
hydrophilicity, the metabolite can demonstrate better safety profile than the parent drug (as observed for 
terfenadine and its metabolite—fexofenadine). Regulatory authorities recommend the study on drug 
metabolites [16,17] in the safety assessment of the drug, thus the determination and characterization 
of systemic metabolites are required. The metabolism of ANT was investigated using only rabbit 
liver microsomal fraction [18]. N-benzylaniline and p-benzylaminophenol were detected as metabolic 
products [18]. No data on ANT metabolism in humans is available, most likely because it was not 
required at the time of registration of the drug (Phenazolinum, Polfa, Poland) containing ANT mesylate. 
Species differences in metabolism are often responsible for the difficulties in extrapolating the metabolic 
data from laboratory animals to humans [19]. Food and Drug Administration (FDA) noted the cases 
for which clinically relevant metabolites have not been identified during preclinical development [16]. 
One of the reasons for this is the differences in the CYP P450 enzyme expression [15] among species. 
Thus, we decided to investigate the metabolism of ANT using human plasma collected from healthy 
volunteers receiving a standard dose of 100 mg of ANT mesylate, intravenously. We also applied the 
in vitro model of pooled human hepatocytes. It was very reasonable to perform the metabolic study of 
ANT as the sensitivity of analytical methods, since the last study reported almost four decades ago [18], 
has been improved enormously. In this study, liquid chromatography coupled with high resolution 
tandem mass spectrometry (LC-HRMS) was used for qualitative and semi-quantitative analysis of 
ANT metabolites. The study was also aimed to investigate the CYP P450 enzyme isoforms involved in
the biotransformation of ANT using cDNA expressed human P450 enzyme preparations co-expressed 
with human NADPH-CYP P450 reductase (Bactosomes™) and LC-HRMS.
2. Results and Discussion
Mass spectrometric characterisation of ANT was performed using positive mode ionization and 
parameters listed in Materials and Methods. Under the conditions applied, ANT formed a protonated 
molecular ion at m/z 266.1649 (0.86 ppm, elemental composition C17H19N3 + H+). The fragment ions 
produced in the collision cell were detected at m/z 196.1124, 175.1107, 174.1025, 161.1075, 118.0654, 
106.0653, 91.0544 and 71.0606. Their proposed structures and monoisotopic masses are presented 
in Figure 1. The tentative structure of metabolites was proposed by comparing m/z values of the 
fragment ions of each metabolite with those of ANT to define the region in the molecule in which the 
transformation occurred.
Figure 1. Monoisotopic mass of protonated molecular ion of ANT M +H + (m/z 266.1652) and its 
fragment ions obtained with a normalized collision energy of 20, 35, 50 eV using Orbitrap Focus.
2.1. Determination of Metabolites in Plasma of Volunteers and Hepatocytes Cultures
The analysis of chromatograms of extracted plasma from volunteers made it possible to identify 
15 potential metabolites of ANT. Their MS data are presented in Table 1 and their tentative structures 
in Figure 2.
Table 1. Experimental molecular weight, the difference between the theoretical and experimental molecular weight, retention time, molecular formula, and the most 




Retention Time [Min] Molecular Formula AMass [ppm] Differences with ANT Detected in v itro 1 MS/MS Ions
M1 (MW189) 189.1263 2.2 C11 H 15N 3 -1 .58 -6C ,4H yes (3.6) 120.0811, 91.0545, 71.0607
M2 (MW281) 281.1525 11.0 C 17H 19N 3O -1 .10 +O yes (6.6)
212.1075, 191.1055, 161.1074, 
122.0603, 91.0545, 71.0607
MW295 295.1320 10.4 C 17H 17N 3 O2 -0 .23 -2H ,+2O yes (6.6)
205.0856, 188.0835, 
91.0545, 71.0601
MW299 299.1634 11.0 C17H 21 N3 O2 0.06 +2H ,2O yes (6.7)
212.1071,149.0475,122.0603, 
91.0543, 72.0444
MW351 351.1427 13.5 C16H 21 N3 O6 -0 .96 -C ,+2H ,6O no _2
MW361 361.1095 11.2 C 17H 19N 3 O 4S -0 .19 +S,4O yes (5.9) _2
M 7 (MW375) 375.1318 6.4 C 1 9H 21N O 7 0.13 +2C ,2H ,7O ,-2N yes (5.6)
358.1306,224.1069,200.1074, 
122.0603, 109.0525, 91.0544
M4 (MW441) 441.1901 12.1 C23 H27 N3 O6 0.45 +6C,8H,6O yes (7.1)
266.1654,196.1125,161.1073, 
91.0545, 71.0606
M8 (MW455) 455.1702 8.7 C23 H25 N3 O7 -1 .70 +6C,6H,7O no
376.1396,280.1448,189.0900, 
91.0544, 71.0127
M3 (MW457) 457.1849 8.2 C23 H27 N3 O7 0.08 +6C,8H,7O yes (4.8)
388.1389, 282.1600,212.1071, 
122.0600,91.0543,71.0606
M5 (MW457b) 457.1850 9.7 C23 H27 N3 O7 0.32 +6C,8H,7O yes (5.3) 282.1607,212.1075,122.0600, 
91.0545, 71.0606 
458.1936,300.1702,282.1605,
MW475 475.1957 9.1 C23 H29 N3 O8 0.69 +6C,10H,8O yes (5.1) 212.1072, 122.0602,
91.0544, 71.0607




M6 (MW487) 487.1957 8.9 C24 H29 N3 O8 0.49 +7C,10H,8O yes (5.1) 221.1161, 152.0708,
91.0544, 71.0606
MW487b 487.1957 9.3 C24 H29 N3 O8 0.55 +7C,10H,8O yes (5.3)
312.1709,176.1187,137.0600, 
106.0655, 71.0605
1 retention time [min] was provided in brackets; 2 low quality MS2 spectra.
MW361 ~
MW487b
Figure 2. The main pathways of ANT metabolism and putative structure of Phase I and Phase II metabolites. The main metabolites are marked as M 1-M 8, 
other metabolites are labelled with molecular weights (MW). Possible intermediate products were marked A -D . A— monoisotopic mass: 297.1477 Da, detected in 
the plasma of volunteers but did not fulfill the criteria of metabolite selection (see Section 2.2); B— monoisotopic mass: 281.1528 Da, not detected in the plasma of 
volunteers, but detected in CYP in vitro metabolism study (CYP2C19), C—monoisotopic mass: 279.1371 Da, detected in the plasma of volunteers but did not fulfill the 
criteria of metabolite selection (see Section 2.2), D— monoisotopic mass: 199.09971 Da, not detected in this study, but described by Ali et al. (1981).
Other parameters like the ring and double bond (RDB) values, hydrogen vs. carbon atoms ratio 
(H/C) values, spectral similarity scores between theoretical and measured isotopic patterns (SFit) 
and matched intensity percentage of the theoretical pattern (Pattern Cov.) are presented in Table A1. 
The typical chromatogram of the most prevalent metabolites is shown in Figure A1. Most of the 
metabolites found in the plasma of volunteers were detected as well in an in vitro assay with human 
hepatocytes (the appropriate annotation is shown in Table 1) . Some of the detected compounds are 
Phase I metabolites including M1, M2, and metabolite of MW295 as well as MW299. Some of the 
detected products are Phase I metabolites, additionally methylated and glucuronidated, including M6, 
MW485, and MW487b. Some of them are conjugated with glucuronic acid (ANT or Phase I metabolite) 
(M3, M4, M5, M7, M8, MW351, MW475) or with sulfuric acid (MW361) only. The main pathways of 
ANT metabolism are shown in Figure 2. M1 is the metabolite of ANT that results from the cleavage 
of the C-N bond and removal of phenyl. In Phase II metabolism, M1 forms N-glucuronide MW351. 
In an alternative path, ANT directly undergoes Phase II metabolism, producing N-glucuronide M4. 
The other Phase I transformation of ANT is hydroxylation in the para position of phenyl substituent, 
leading to metabolite M2. This metabolite is further conjugated with glucuronic acid to form N - or 
O-glucuronide (M5 and M3, respectively) or with sulfuric acid forming sulfate MW361. Alternatively, 
cleavage of the imidazole ring of metabolite M2, followed by hydration gives MW299 and further 
conjugation with glucuronic acid gives MW475. Since in an in vitro post-reaction mixture hydrated 
ANT was detected it cannot be excluded that in another pathway ANT is firstly hydrated and then 
hydroxylated to form MW299. M2 is also hydroxylated to give metabolite A and then glucuronidated 
followed by methylation to form M6 and MW487b. Compound A was detected in the plasma of 
volunteers but it did not fulfill the criteria of metabolite selection as a lower increase in peak area than 
expected for a metabolite was recorded. ANT is also hydroxylated at the alpha position to the imidazole 
ring, producing compound B. This is then hydroxylated to the rvespective ketone C. Compound B 
was not detected in an in vivo study, but it was found in the post-reaction mixture with CYP2C19. 
Compound C was detected in the plasma of volunteers but did not fulfill the criteria of metabolite 
selection. Compound C was then conjugated with glucuronic acid to give M8 or hydroxylated to form 
MW295 followed by methylation of phenolic hydroxyl and glucuronidated to give MW485. However, 
MW295 may be formed by oxidation of compound A as well. Another metabolite of ANT might be 
a compound D, as M2 without 2-methyl-4,5-dihydro-1H-imidazole fragment. Glucuronidation of 
compound D resulted in the formation of metabolite M7. Compound D was not detected in this study, 
but it was reported previously as a rabbit metabolite of ANT [18].
The structure of most of the metabolites was confirmed by their fragmentation patterns. 
The fragment ions of protonated M1, produced in the collision cell, were detected at m/z 120.0811, 
91.0545, 71.0607. Their monoisotopic masses and structures are shown at Figure 3.
The postulated fragmentation pathway of the second most important Phase I metabolite (M2) was 
similar to that of ANT, resulting in ions m/z 212.1075,191.1055,122.0603 by the addition of 16 Da at m/z 
196,175,106. Other detected fragments were the same as for ANT, at m/z 161.1074,91.0545, and 71.0607 
(Figure 3). This indicated that the oxidation occurred at phenyls or methyl that were neighboring 
imidazole (Figure 4) . The comparison of the retention time and fragmentation pattern of M2 and that 
of synthesized hydroxyl ANT derivative (to be published elsewhere) confirmed the oxidation at the 
para position in phenyl (Figure A3).
One of the most prevalent Phase II metabolite of ANT was N -glucuronide, M4. The MS2 
ions were identical with that of ANT at m/z at 266.1654, 196.1125, 118.0656, and 91.0544, 71.0606 
(Figure A2). The second Phase II metabolite of great importance was O-glucuronide of hydroxy ANT 
(M3). We observed the fragments similar to those in the hydroxy ANT (M2) spectrum at m/z 282.1600, 
212.1071,122.0600, 91.0543, 71.0606. Additionally, ion at m/z 388.1389 formed by the addition of 176 Da 
to m/z 212, observed in the spectrum of M2 was detected. The other fragmentation pathway was 
observed for N-glucuronide of hydroxy ANT (M5). None of the fragments contained the glucuronic 
acid moiety. The main fragments were m/z 282.1607,212.1075,122.0600,91.0545 and 71.0606 (Figure A2).
The kinetics of changes in the intensity of ions of selected metabolites (a relative increase in peak 
area greater than 10 in at least three sampling points) are presented at Figure 5.
Figure 3. Monoisotopic mass of protonated molecular ion (M +H +) of the main ANT Phase I metabolites: 
M1 (m/z 190.1340) and M2 (m/z 282.1601) and their fragment ions obtained with a normalized collision 
energy of 20 ,35 ,50  eV using Orbitrap Focus. Pseudo-molecular ions of M1 and M2 were marked in red.
Figure 4. The structures of the two most abundant Phase I metabolites of ANT: M1 and M2. The structure 
of M2 was confirmed by chemical synthesis.
Figure 5. The relative changes of peak areas of metabolites in plasma of two volunteers after 
administration of ANT. The molecular weights of metabolites are given in Table 1. Only the compounds 
with increased intensities greater than 10, in at least three sampling points, are presented.
The maximum peak areas of the metabolites detected (relative to ANT peak) in plasma and 
hepatocytes culture were presented in Figure 6. In the plasma, the highest peak area was recorded 
for M1 (ANT without phenyl) followed by M2 (hydroxy ANT), M3 (glucuronide of hydroxyl ANT), 
and M4 (N-glucuronide of ANT), whereas for in vitro assay the most prominent metabolite was M2, 
followed by M4, M3, and M1.
Figure 6. (a) The relative maxim um peak area (maximum metabolite area divided by the maxim um 
peak area of ANT) of detected metabolites in plasma after administration of ANT (b). The relative peak 
area (the metabolite area divided by the peak area of AN T) of metabolites detected after 120 min of 
incubation with pooled human hepatocytes.
The metabolite of ANT described by Ali et al. [18], p-benzylaminophenolate, with the monoisotopic 
mass of 199.099, was not detected in our study. However, we detected its glucuronide M7 
(MW375). Another metabolite described previously, N-benzylaniline (monoisotopic mass 183.1048), 
was detected [18], but its concentration was highly correlated with the ANT peak area (r = 0.92, p <  0.05). 
Thus, it was not considered in this paper. The differences in the pattern of metabolites observed in our 
study might result from the different metabolisms among various species.
2.2. In Vitro Analysis Using Various CYP Isoforms
The metabolism of ANT with CYP2D6 was fast (Figure A4). Less than 1% of the parent compound 
was detected after 5 min of incubation. The metabolism of ANT with CYP2C19 was much slower. 
After 5 and 30 min of reaction, 89% and 50%, respectively, of ANT remained unchanged. ANT was 
found to not to be the substrate for other cytochrome isoforms i.e., CYP1A2, CYP2C8, CYP2C9 and 
CYP3A6. In the incubation mixture, the two major Phase I metabolites of ANT, i.e., M1 and M2, 
were detected. M1 and M2 were found in CYP2D6 post-reaction mixture. M2, together with metabolite 
B (MW281, Figure 2), compound A (Figure 2), and compound C (Figure 2), was also detected as the 
product of the reaction catalyzed by CYP2C19. None of the metabolites were observed in the control 
samples (no CYP P450 enzymes present). CYP2D6 metabolizes more than 25% of clinically used 
drugs [20]. The CYP2D6 encoding gene is highly polymorphic with more than 100 allelic variants. 
High polymorphism of the enzyme causes a different rate of drug metabolism. According to the activity 
of CYP2D6, the population is categorized as poor, extensive, and ultra-rapid metabolizers. In Europe, 
ultra-rapid metabolizers (i.e., CYP2D6 duplication) are the most frequently detected in the South-East 
European countries, where represent up to 6% of the population. Substantially lower frequencies 
are observed in Northern and Central Europe (1.6-0.5%). Globally, CYP2D6 duplication is the most 
common in North-East Africa and the Middle East with frequencies of 7-16%. Poor metabolizers 
are more prevalent than ultra-rapid metabolizers and vary between 15.7% in Finland and Turkey, 
and 33.6% in the Faroe Islands [21]. Thus, the genetic polymorphism strongly influences the ANT 
metabolism, which should be taken into account in optimization of the therapy for various groups 
of patients.
3. Materials and Methods
3.1. Sample Preparation
3.1.1. In Vivo Analysis
ANT mesylate (Phenazolinum, Polfa, Poland) was given intravenously in 100 mg bolus injected 
during 1 min (the equivalent of 73.4 mg of ANT) to 2 healthy volunteers. Approximately, 2 mL blood 
samples were collected (sodium citrate as anticoagulant, 3.2%) before and at 2 ,4 , 6, 8 ,10,30, 60,180, 
240 and 300 min post-dose. Immediately after collection, blood samples were centrifuged at 2000X g  for 
15 min at room temperature and plasma samples were aliquoted and stored at-80 °C before analysis. 
Plasma samples (0.1 mL) were diluted with the mixture of methanol and ethanol (Merck Millipore, 
Darmstadt, Germany) (1:1, v/v, 0.7 mL) containing 0.15 gg/mL of xylometazoline (surrogate standard) 
(Toronto Research Chemicals, Toronto, Canada) and put at -2 0  °C for 30 min. Then, samples were 
centrifuged (10 min, at 2000X g), and the supernatant was evaporated to dryness (40 °C). The residue 
was reconstituted in 10% aqueous acetonitrile (Merck Millipore, Darmstadt, Germany) (0.1 mL) and 
10 gL aliquot was injected into the LC-HRMS. The quality control consisted of equal volumes of each 
sample. Blank solvent and blank control of a matrix sample with and without antazoline was included 
in the analytical run as well.
3.1.2. In Vitro Analysis
ANT metabolism was studied in vitro by Cyprotex (Alderley Park, UK) according to their internal 
procedure and was conducted on ANT mesylate in 10-donor mixed gender pooled hepatocytes 
samples (LiverPool™, BioreclamationIVT) for 120 min. The hepatocytes had documented activity 
of ethoxycoumarin-O-deethylase (ECOD), uridine 5'-diphospho-glucuronosyltransferase (UGT), 
sulfurtransferase (ST), CYP1A2, CYP2A5, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, 
and CYP3A4. Incubations (500 gL) were performed at a concentration of 3 gM at 37 °C. The cell density 
was 0.5 X 106 viable cells/mL. The final dimethyl sulfoxide (DMSO) concentration in the incubation was
0.25%. Control incubations were also performed in lysed cells to reveal any non-enzymatic degradation. 
Samples were removed from the incubation mixture at 0 and 120 min and added to acetonitrile (1:2, 
v/v), containing surrogate standard (metoprolol, 0.55 gM), to terminate the reaction. The samples were 
centrifuged (2500 rpm at 4 °C for 30 min) and the pooled supernatants were analyzed by LC-HRMS.
To determine the possible CYP isoforms involved in the metabolism of ANT, ANT mesylate 
(1 gM) was incubated with CYP1A2, CYP3A6, CYP2C8, CYP2C9, CYP2C19 and CYP2D6 expression 
systems (Bactosomes™) by Cyprotex according to their internal procedure. Bactosomes™ (final P450 
concentration: CYP1A2 100 pmol/mL, CYP2C8 50 pmol/mL, CYP2C9 25 pmol/mL, CYP2C19 
100 pmol/mL, CYP2D6 50 pmol/mL and CYP3A4 25 pmol/mL), 0.1 M phosphate buffer pH 7.4 
and ANT were pre-incubated at 37 °C prior to the addition of reduced form of nicotinamide adenine 
dinucleotide phosphate (NADPH, final concentration 1 mM) to initiate the reaction. Incubations were 
also performed using control Bactosomes™ (no P450 enzymes present) to reveal any non-enzymatic 
degradation. Control compounds known to be metabolized specifically by each P450 isoform are 
included. ANT was incubated for 0, 5, 15, 30, and 45 min with each isoform. The reactions was 
stopped by transferring an aliquot of the incubate to a quenching solvent, containing surrogate 
standard (acetonitrile with metoprolol at 0.55 gM), at the appropriate time points, in a 1:3 (v/v) ratio. 
The termination plates was centrifuged at 3000 rpm for 20 min at 4 °C to precipitate the protein.
3.2. Instrumental Analysis
3.2.1. In Vivo Analysis
Instrumental analysis was performed using a Dionex Ultimate 3000 with a Q-Exactive hybrid 
quadrupole-Orbitrap mass spectrometer system (Thermo Fisher Scientific, Waltham, MA, USA) 
equipped with heat electrospray ionization (HESI), an online vacuum degasser, a quaternary pump, 
an autosampler, and a thermostatic column compartment. The HESI was operated in a positive 
mode. Full MS scans were acquired over an m/z 70-600 range with a resolution of 70,000 (m/z 200). 
The target value was 3 X 106. Fragmentation was performed in different runs with a normalized 
collision energy of 20,35,50 eV. The tandem mass spectrum was acquired with resolution 17,500 at m/z 
200. The target value was 5 X 104. The ion selection threshold was 8 X 103 counts, and the maximum 
allowed ion accumulation times were set to auto both for full MS scans and for the tandem mass 
spectrum. Standard mass spectrometric conditions for all experiments were: spray voltage, 3.5 kV; 
sheath gas pressure: 60 arb; aux gas pressure: 20 arb; sweep gas pressure: 0 arb; heated capillary 
temperature: 320 °C; loop count: 3; isolation window: m/z 1.0; and dynamic exclusion: 6.0 s. For all 
full scan measurements, lock-mass ions from ambient air (m/z 445.1200 and 291.2842) were used as 
internal calibrants. All data collected in profile mode were acquired and processed using Xcalibur 3.0 
software (Thermo Fisher Scientific, Waltham, MA, US), and Compound Discoverer 2.1 (Thermo Fisher 
Scientific, Waltham, MA, US), respectively. Chromatographic separation was achieved with a Kinetex 
RP-18 column (100 mm X 4.6 mm, 2.6 gm) supplied by Phenomenex (Torrance, CA, USA) equipped 
with a security guard. The column was maintained at 40 °C at a flow rate of 0.5 mL/min. The mobile 
phases consisted of HPLC grade water with 0.1% formic acid (Merck Millipore, Darmstadt, Germany) 
as eluent A and acetonitrile with 0.1% formic acid as eluent B. The gradient (% B) was as follows: 
3.5 min-10%; 30 min-90%; 39.5 min-90%. The volume of injection was 10 gL. Every five samples,
quality control was run. To validate the analytical precision, a principal component analysis (PCA) 
was conducted. In the scatter plot of principal components, all quality controls were clustered in two 
separate groups.
The compound was considered as a metabolite when it met the following requirements:
1. The proposed formula corresponded to products of Phase I or Phase II 
metabolic biotransformations.
2. The peak area of the compound increased at least five times and at least in three sampling 
timepoints (vs. time 0) with a gradual increase after drug administration in plasma of 
both volunteers.
3. The difference between experimental and theoretical molecular weight was not higher than 
5 ppm.
3.2.2. In Vitro Analysis
Instrumental analysis was performed by Cyprotex using a Waters XevoQTof G2-S system (Milford, 
MA, USA) equipped with an Acquity Binary Solvent Manager, Acquity Column Manager and 
2777 Autosampler (Milford, MA, USA). The electrospray ionization (ESI) source was operated in a 
positive mode.
Full MS scans were acquired over the m/z 130-1000 range. Fragmentation was performed with a 
collision energy ramp from 10 to 40 V. Spray voltage was 0.3 kV and cone voltage 40 V. For all full scan 
measurements, lock-mass ions of leucine enkephalin (0.4 gg/mL, 10 gL/min) were used as internal 
calibrants. Chromatographic separation was achieved with a C18 ACQUITY UPLC® HSS T3 column 
(Thermo Fisher Scientific, Waltham, MA, US) (100 mm X 2.1 mm, 1.8 gm). The column was maintained 
at 60 °C at a flow rate of 0.4 mL/min. The mobile phases consisted of 10 mM ammonium formate with 
0.1% formic acid as eluent A and acetonitrile with 0.1% formic acid as eluent B. The gradient (% B) was 
as follows: 0.5 min—2%; 10 min—35%; 11 min—95%. The volume of injection was 10 gL. The data was 
processed using Metabolynx XS (Waters Ltd., Milford, MA, US). The 120-min samples were compared 
against the 0-min control sample.
To determine the possible CYP isoforms, instrumental analysis was performed using a Dionex 
Ultimate 3000 with a Q-Exactive hybrid quadrupole-Orbitrap mass spectrometer as described in the
in vivo analysis section.
4. Conclusions
The present in vitro study revealed CYP2D6 as the main CYP isoform involved in the metabolism 
of ANT. Since the enzyme is highly polymorphic, the intensities of metabolites in the metabolic profile 
of ANT in humans can exhibit high inter-individual variation. This should be considered in the 
selection of the ANT dose in a particular AF treatment. Human metabolism of ANT includes both 
Phase I and Phase II reactions, which are mainly glucuronidation. In this study, we showed that 
ANT was metabolized to at least 15 compounds. The most prominent Phase I metabolite of ANT 
is M1 (N-benzyl-1-(4,5-dihydro-1H-imidazole-2-yl)methanamine), formed by the removal of phenyl 
and metabolite M2 resulting from introducing hydroxyl into phenyl in the para position of ANT. M2, 
as the hydroxylated analog of ANT, might be less toxic than ANT due to its higher hydrophilicity, and, 
as the compound structurally close to ANT, might also reveal similar antiarrhythmic effects. However, 
since metabolic hydroxylation might lead to compounds that are either less or more potent than the 
parent drug, further research in this direction is needed. Studies on pharmacological activity, potency, 
toxicity, and pharmacokinetics of the metabolites would allow us to better understand the activity 
profile of ANT and to predict its potential clinical application. Ultimately, these studies might result in 
the development of a new drug substance.
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Appendix A
Table A1. Experimental molecular weights, ring and double bond (RDB) values, hydrogen vs. carbon 
atoms ratio (H/C) values, spectral similarity scores between theoretical and measured isotopic patterns 






RD BE H/C SFit [%] Pattern Cov. [%]
MW189 189.1263 6 1.4 84 99.88
MW281 281.1525 10 1.1 89 99.91
MW295 295.1320 11 1 92 98.37
MW299 299.1634 9 1.2 98 98.37
MW351 351.1427 8 1.3 82 97.77
MW361 361.1095 10 1.1 76 95.45
MW375 375.1318 10 1.1 96 97.1
MW441 441.1901 12 1.2 65 100
MW455 455.1702 13 1.1 85 99.55
MW457 457.1849 12 1.2 78 100
MW457b 457.1850 12 1.2 85 100
MW475 475.1957 11 1.3 95 95.96
MW485 485.1795 13 1.1 89 95.74
MW487 487.1957 12 1.2 82 99.47
MW487b 487.1957 12 1.2 91 95.74
Figure A1. The example chromatogram of metabolites extracted from plasma of volunteers after 











































































Figure A2. The MS2 spectra of the most prominent antazoline metabolites.
Figure A3. Chromatograms and MS2 spectra of MW281 (M2): synthesized and detected in plasma of 
volunteers after administration of antazoline mesylate.
Figure A4. Changes of ANT peak area after ANT incubation with cytochromes: CYP1A2, CYP3A6, 
CYP2C8, CYP2C9, CYP2C19 and CYP2D6 expression systems (Bactosomes™). In the control sample, 
no CYP P450 enzymes were present.
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